Esporg Duo Sustained Release Tablet 10/1000 Milligrams
Dapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Samchundang Pharm Co., Ltd.
MFDS item code 202300153 · Approved 2023.01.06
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used in combination with dietary management and exercise therapy, to help control blood sugar in adult patients with type 2 diabetes using dapagliflozin and metformin. In patients who do not achieve adequate blood sugar control, particularly those with cardiovascular disease or risk factors, it is important to consult expert advice regarding the impact of dapagliflozin on cardiovascular events. This medication helps to effectively manage blood sugar levels and prevent the complications associated with diabetes.
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients who have not previously received pharmacological treatment for diabetes and for whom adequate glycemic control is difficult to achieve with monotherapy: When used as initial therapy in patients who have not previously received pharmacological treatment for diabetes, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. The dose should be titrated gradually to reduce gastrointestinal adverse effects of metformin. In patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily. The dose of this medicine should provide the dose of metformin the patient was taking, or the nearest therapeutically appropriate dose. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately. In patients switching from combination therapy with dapagliflozin and metformin to this medicine, the dose of this medicine may be started at the doses of dapagliflozin and metformin previously being taken. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from another glucose-lowering medication. Because changes may cause alterations in glycemic control, any change in treatment of patients with type 2 diabetes should be made with careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2, who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Use of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Metformin is excreted through the kidneys, and renal function is more likely to decline in older adults; therefore, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient section).
This medication can cause a rare complication called severe lactic acidosis, so it should not be used by patients with impaired kidney function, serious infections, dehydration, or cardiovascular issues. Care should be taken as there is a risk of hypoglycemia when this medication is used with insulin or sulfonylurea diabetes drugs. Patients with decreased kidney function or low fluid volume should consult a physician before using this medication and carefully check kidney function and fluid status. Pregnant or breastfeeding women should not take this medication, and should cease administration immediately if pregnancy is confirmed. This medication may increase the risk of genital infections or urinary tract infections, and timely treatment should be sought if any infection symptoms appear. Dehydration or low blood pressure symptoms due to reduced fluid volume may occur; if dizziness or blood pressure drops are noted, inform a doctor. Vitamin B12 deficiency may occur, so it is advisable to periodically check blood vitamin B12 levels during long-term use. Excessive alcohol consumption should be avoided while taking this medication, and if surgery or imaging tests are scheduled, it may be necessary to suspend the medication for a certain period before and after. Elderly patients or those with decreased kidney function should have their medication dosage adjusted and kidney function monitored frequently. This medication can cause hypoglycemia, so when used in combination with blood sugar-lowering agents, attention should be paid to hypoglycemic symptoms, and doses may need adjusting accordingly. In the case of overdose, seek medical attention immediately, as side effects such as dizziness may be present, necessitating caution when driving or operating machinery. Store this medication out of the reach of children, and keep in its original container.
severe lactic acidosis, severe hypoglycemia, vulvovaginitis, balanitis, genital infection, urinary tract infection, fungal infection, hypoglycemia, decreased fluid volume, thirst, diabetic ketoacidosis, dizziness, constipation, dry mouth, low back pain, dysuria, polyuria, nocturia, vulvar itching, genital itching, increased hematocrit, decreased creatinine clearance in the kidney, dyslipidemia, elevated serum creatinine, elevated blood urea, weight loss, ketosis, urosepsis, pyelonephritis, acute kidney injury, renal dysfunction, rash, diarrhea, nausea, vomiting, decreased vitamin B12, Guillain-Barré syndrome, bacterial pneumonia, sialadenitis, tendinitis, chest pain, thermal burn, wrist fracture, gastrointestinal stromal tumor, malignant neoplasm of the lung, uterine fibroids, atrial fibrillation, acute cholecystitis, upper abdominal pain, dyspepsia, abdominal discomfort, abdominal pain, gastric ulcer, irritable bowel syndrome, salivary gland mass, toothache, headache, facial paralysis, peripheral neuropathy, sensory abnormalities, drowsiness, tremor, nasopharyngitis, pharyngitis, adenoviral conjunctivitis, herpes zoster, pneumonia, rhinitis, increased alanine aminotransferase, increased blood sugar, arthralgia, myalgia, myofascial pain syndrome, osteoarthritis, osteochondrosis, limb pain, periarticular inflammation, tenosynovitis, trigger finger, myasthenia, fatigue, peripheral edema, swelling, pain, vitamin D deficiency, hyperglycemia, urethral syndrome, cough, hyperventilation, itching, palpitations, insomnia, type 2a hyperlipidemia, neurogenic hearing loss, acute cholecystitis
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent air or moisture from entering, and it is safe to store at room temperature between 1 degree and 30 degrees Celsius. Proper storage will maintain the medication's efficacy and prevent deterioration.
Yellow, elliptical, convex, sustained-release film-coated tablet
30 tablets/box [(6 tablets/PTP*5)], 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Dapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Samchundang Pharm Co., Ltd.
CombinationDapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Daewoo Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
CombinationDapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Il-Yang Pharmaceutical Co., Ltd.
CombinationDapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
HK inno.N Co., Ltd.
CombinationDapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kyungbo Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Albogen Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.